1.Renal cell carcinoma bony metastasis treatment.
Saminathan Suresh NATHAN ; Chin Tat LIM ; Benjamin Y S CHUAH ; Thomas C PUTTI ; Anthony J STANLEY ; Alvin S C WONG
Annals of the Academy of Medicine, Singapore 2008;37(3):247-248
Bone Neoplasms
;
diagnosis
;
secondary
;
Carcinoma, Renal Cell
;
diagnosis
;
secondary
;
Humans
;
Kidney Neoplasms
;
pathology
;
Male
;
Middle Aged
;
Patella
;
Sternum
2.Outcomes after robot-assisted laparoscopic radical prostatectomy.
Declan G MURPHY ; Benjamin J CHALLACOMBE ; Anthony J COSTELLO
Asian Journal of Andrology 2009;11(1):94-99
Robot-assisted laparoscopic radical prostatectomy (RALRP) using the da Vinci surgical system is now in widespread use in many countries where economic conditions allow the installation of this expensive technology. Controversy has surrounded the procedure since it was first performed in 2000, with many critics highlighting the lack of evidence to support its use. However, despite the lack of level I evidence, many large studies of patients have confirmed that the procedure is feasible and safe, with low morbidity. Available longer-term oncological data seem to show that outcomes from the robotic approach at least match those of traditional open radical prostatectomy. Functional outcomes also seem satisfactory, although randomized controlled trials are lacking. This paper reviews the current status of RALRP with respect to perioperative data and complications and oncologic and functional outcomes.
Erectile Dysfunction
;
etiology
;
Humans
;
Laparoscopy
;
methods
;
trends
;
Male
;
Prostatectomy
;
adverse effects
;
instrumentation
;
methods
;
Prostatic Neoplasms
;
surgery
;
Robotics
;
methods
;
trends
;
Treatment Outcome
;
Urinary Incontinence
;
etiology
3.Pathogenic variant in NLRP7 (19q13.42) associated with recurrent gestational trophoblastic disease: Data from early embryo development observed during in vitro fertilization.
E Scott SILLS ; Alexandra J OBREGON-TITO ; Harry GAO ; Thomas K MCWILLIAMS ; Anthony T GORDON ; Catharine A ADAMS ; Rima SLIM
Clinical and Experimental Reproductive Medicine 2017;44(1):40-46
OBJECTIVE: To describe in vitro development of human embryos derived from an individual with a homozygous pathogenic variant in NLRP7 (19q13.42) and recurrent hydatidiform mole (HM), an autosomal recessive condition thought to occur secondary to an oocyte defect. METHODS: A patient with five consecutive HM pregnancies was genomically evaluated via next generation sequencing followed by controlled ovarian hyperstimulation, in vitro fertilization (IVF) with intracytoplasmic sperm injection, embryo culture, and preimplantation genetic screening. Findings in NLRP7 were recorded and embryo culture and biopsy data were tabulated as a function of parental origin for any identified ploidy error. RESULTS: The patient was found to have a pathogenic variant in NLRP7 (c.2810+2T>G) in a homozygous state. Fifteen oocytes were retrieved and 10 embryos were available after fertilization via intracytoplasmic sperm injection. Developmental arrest was noted for all 10 embryos after 144 hours in culture, thus no transfer was possible. These non-viable embryos were evaluated by karyomapping and all were diploid biparental; two were euploid and eight had various aneuploidies all of maternal origin. CONCLUSION: This is the first report of early human embryo development from a patient with any NLRP7 mutation. The pathogenic variant identified here resulted in global developmental arrest at or before blastocyst stage. Standard IVF should therefore be discouraged for such patients, who instead need to consider oocyte (or embryo) donation with IVF as preferred clinical methods to treat infertility.
Abortion, Habitual
;
Aneuploidy
;
Biopsy
;
Blastocyst
;
Diploidy
;
Embryonic Development*
;
Embryonic Structures*
;
Female
;
Fertilization
;
Fertilization in Vitro*
;
Genetic Testing
;
Gestational Trophoblastic Disease*
;
Humans
;
Hydatidiform Mole
;
In Vitro Techniques*
;
Infertility
;
Oocytes
;
Parents
;
Ploidies
;
Pregnancy
;
Sperm Injections, Intracytoplasmic
4.Novel association between sperm deformity index and oxidative stress-induced DNA damage in infertile male patients.
Tamer M SAID ; Nabil AZIZ ; Rakesh K SHARMA ; Iwan LEWIS-JONES ; Anthony J THOMAS ; Ashok AGARWAL
Asian Journal of Andrology 2005;7(2):121-126
AIMTo investigate the impact of abnormal sperm morphology using the sperm deformity index (SDI) on reactive oxygen species (ROS) production and its correlation with sperm DNA damage.
METHODSSemen samples were collected from men undergoing infertility screening (n = 7) and healthy donors (n = 6). Mature spermatozoa were isolated and incubated with 5 mmol/L beta-nicotinamide adenine dinucleotide phosphate (NADPH) for up to 24 h to induce ROS. Sperm morphology was evaluated using strict Tygerberg's criteria and the SDI. ROS levels and DNA damage were assessed using chemiluminescence and terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labeling (TUNEL) assays, respectively.
RESULTSSDI values (median [interquartiles]) were higher in patients than donors (2 [1.8, 2.1] vs. 1.53 [1.52, 1.58], P = 0.008). Aliquots treated with NADPH showed higher ROS levels (1.22 [0.30, 1.87] vs. 0.39 [0.10, 0.57], P = 0.03) and higher incidence of DNA damage than those not treated (10 [4.69, 24.85] vs. 3.85 [2.58, 5.10], P = 0.008). Higher DNA damage was also seen following 24 h of incubation in patients compared to donors. SDI correlated with the percentage increase in sperm DNA damage following incubation for 24 h in samples treated with NADPH (r = 0.7, P = 0.008) and controls (r = 0.58, P = 0.04).
CONCLUSIONSDI may be a useful tool in identifying potential infertile males with abnormal prevalence of oxidative stress (OS)-induced DNA damage. NADPH plays a role in ROS-mediated sperm DNA damage, which appears to be more evident in infertile patients with semen samples containing a high incidence of morphologically abnormal spermatozoa.
DNA Damage ; Humans ; Infertility, Male ; genetics ; pathology ; Male ; Oxidative Stress ; Reactive Oxygen Species ; Spermatozoa ; abnormalities
5.Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience.
Maher ABDESSATER ; William AKAKPO ; Anthony KANBAR ; Jérome PARRA ; Thomas SEISEN ; Emmanuel CHARTIER-KASTLER ; Sarah J DROUIN ; Morgan ROUPRET
Asian Journal of Andrology 2022;24(1):45-49
The aim of this article is to assess the outcomes of a low-intensity extracorporeal shock wave therapy (LiESWT) protocol for the treatment of Peyronie's disease (PD). Patients treated for PD were prospectively recorded, and data were retrospectively reviewed. Age, characteristics of fibrous plaques, concomitant treatments, International Index of Erectile Function (IIEF-5), Lue score, and pain score on Likert scale were collected. Patients in acute phase of PD and an angulation of <40° were included. The protocol consisted of 6 weekly sessions of 4000 pulses each, applied from different directions, with a maximal power of 20 W and 8 Hz frequency. We included 39 patients (median age: 56.8 years, interquartile range [IQR]: 35.8-62.2 years). The median number of sessions received per patient was 7.2. After treatment, the median Lue score decreased from 6.8 initially to 3.3 (P = 0.003), the median Likert pain score dropped from 1.8 to 0.7 (P = 0.004), the median plaque size was reduced from 2 cm to 1.2 cm (P = 0.08), and the median penile curvature diminished from 31° to 17° (P = 0.07). On univariate and multivariate analysis, the only predictors of success were younger age (odds ratio [OR] = 0.95, P = 0.03 and OR = 0.91, P = 0.04, respectively) and concomitant use of phosphodiesterase-5 inhibitors (PDE5i; OR = 0.92, P = 0.02 and OR = 0.93, P = 0.01, respectively). LiESWT had a favorable impact on Lue score and notably penile pain, curvature, plaque size, and erectile function in patients treated for PD during the early inflammatory phase, with no side effects. Younger age and concomitant use of PDE5i were the only success predictors.
Adult
;
Extracorporeal Shockwave Therapy
;
Humans
;
Male
;
Middle Aged
;
Penile Erection
;
Penile Induration/therapy*
;
Penis
;
Retrospective Studies
;
Treatment Outcome